These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Bacillus calmette-guerin as a quick and temporary solution to coronavirus disease-2019. Kumari P; Gupta UD; Bhagyawant SS Int J Mycobacteriol; 2021; 10(2):105-110. PubMed ID: 34558459 [TBL] [Abstract][Full Text] [Related]
25. Bacillus Calmette-Guérin-induced trained immunity protects against SARS-CoV-2 challenge in K18-hACE2 mice. Zhang BZ; Shuai H; Gong HR; Hu JC; Yan B; Yuen TT; Hu YF; Yoon C; Wang XL; Hou Y; Lin X; Huang X; Li R; Au-Yeung YM; Li W; Hu B; Chai Y; Yue M; Cai JP; Ling GS; Hung IF; Yuen KY; Chan JF; Huang JD; Chu H JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35446790 [TBL] [Abstract][Full Text] [Related]
26. Sequence similarity of HSP65 of Mycobacterium bovis BCG with SARS-CoV-2 spike and nuclear proteins: may it predict an antigen-dependent immune protection of BCG against COVID-19? Finotti P Cell Stress Chaperones; 2022 Jan; 27(1):37-43. PubMed ID: 34755305 [TBL] [Abstract][Full Text] [Related]
27. Multiple BCG vaccinations for the prevention of COVID-19 and other infectious diseases in type 1 diabetes. Faustman DL; Lee A; Hostetter ER; Aristarkhova A; Ng NC; Shpilsky GF; Tran L; Wolfe G; Takahashi H; Dias HF; Braley J; Zheng H; Schoenfeld DA; Kühtreiber WM Cell Rep Med; 2022 Sep; 3(9):100728. PubMed ID: 36027906 [TBL] [Abstract][Full Text] [Related]
28. Safety and COVID-19 Symptoms in Individuals Recently Vaccinated with BCG: a Retrospective Cohort Study. Moorlag SJCFM; van Deuren RC; van Werkhoven CH; Jaeger M; Debisarun P; Taks E; Mourits VP; Koeken VACM; de Bree LCJ; Ten Doesschate T; Cleophas MC; Smeekens S; Oosting M; van de Veerdonk FL; Joosten LAB; Ten Oever J; van der Meer JWM; Curtis N; Aaby P; Stabell-Benn C; Giamarellos-Bourboulis EJ; Bonten M; van Crevel R; Netea MG Cell Rep Med; 2020 Aug; 1(5):100073. PubMed ID: 32838341 [TBL] [Abstract][Full Text] [Related]
29. Effects of Bacille Calmette Guerin (BCG) vaccination during COVID-19 infection. Chowdhury UN; Faruqe MO; Mehedy M; Ahmad S; Islam MB; Shoombuatong W; Azad AKM; Moni MA Comput Biol Med; 2021 Nov; 138():104891. PubMed ID: 34624759 [TBL] [Abstract][Full Text] [Related]
30. VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including Coronavirus Disease 2019 in the Elderly: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study. Blossey AM; Brückner S; May M; Parzmair GP; Sharma H; Shaligram U; Grode L; Kaufmann SHE; Netea MG; Schindler C Clin Infect Dis; 2023 Apr; 76(7):1304-1310. PubMed ID: 36358012 [TBL] [Abstract][Full Text] [Related]
31. BCG Vaccination Program Mitigates COVID19 Related Mortality: A Reality Check. Pandita A; Bhat A; Koul A; Singh SK Curr Pharm Biotechnol; 2021; 22(12):1574-1583. PubMed ID: 33530904 [TBL] [Abstract][Full Text] [Related]
32. The influence of vaccination against tuberculosis with the Bacillus-Calmette-Guérin(BCG) vaccine on COVID-19 incidence and mortality - review of the literature. Ręka G; Korzeniowska A; Piecewicz-Szczęsna H Przegl Epidemiol; 2020; 74(2):290-302. PubMed ID: 33115218 [TBL] [Abstract][Full Text] [Related]
33. BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In silico analyses and a hypothesis. Tomita Y; Sato R; Ikeda T; Sakagami T Vaccine; 2020 Sep; 38(41):6352-6356. PubMed ID: 32863070 [TBL] [Abstract][Full Text] [Related]
34. Effect of BCG Vaccination against SARS-CoV-2 Infection. Li YP; Cai JW; Liao LJ; Ding H; Cao XJ; Zhu GD; Guo XG Jpn J Infect Dis; 2022 May; 75(3):302-308. PubMed ID: 34853192 [TBL] [Abstract][Full Text] [Related]
35. Large-Scale Structure-Based Screening of Potential T Cell Cross-Reactivities Involving Peptide-Targets From BCG Vaccine and SARS-CoV-2. Tarabini RF; Rigo MM; Faustino Fonseca A; Rubin F; Bellé R; Kavraki LE; Ferreto TC; Amaral Antunes D; de Souza APD Front Immunol; 2021; 12():812176. PubMed ID: 35095907 [TBL] [Abstract][Full Text] [Related]
36. BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers. Rivas MN; Ebinger JE; Wu M; Sun N; Braun J; Sobhani K; Van Eyk JE; Cheng S; Arditi M J Clin Invest; 2021 Jan; 131(2):. PubMed ID: 33211672 [TBL] [Abstract][Full Text] [Related]
37. Tuberculosis vaccine BCG: the magical effect of the old vaccine in the fight against the COVID-19 pandemic. Aspatwar A; Gong W; Wang S; Wu X; Parkkila S Int Rev Immunol; 2022; 41(2):283-296. PubMed ID: 33960271 [TBL] [Abstract][Full Text] [Related]
38. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Akova M; Unal S Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629 [TBL] [Abstract][Full Text] [Related]
39. Off-target effects of bacillus Calmette-Guérin vaccination on immune responses to SARS-CoV-2: implications for protection against severe COVID-19. Messina NL; Germano S; McElroy R; Rudraraju R; Bonnici R; Pittet LF; Neeland MR; Nicholson S; Subbarao K; Curtis N; Clin Transl Immunology; 2022; 11(4):e1387. PubMed ID: 35573165 [TBL] [Abstract][Full Text] [Related]
40. Does BCG provide long-term protection against SARS-CoV-2 infection? A case-control study in Quebec, Canada. Pépin J; Labbé AC; Carignan A; Parent ME; Yu J; Grenier C; Beauchemin S; De Wals P; Valiquette L; Rousseau MC Vaccine; 2021 Dec; 39(50):7300-7307. PubMed ID: 34493410 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]